Company intelligence / Profile preview
Valerio Therapeutics
Paris, Francevaleriotx.com ↗
- Ownership
- Public · ALVIO
- Development stage
- Other
01
Overview
In February 2025, Valerio Therapeutics announced a strategic refocus to discontinue all clinical trials, including the VIO-01 trial, due to financing challenges. The company is now focusing exclusively on early-stage drug development[4][5].
- Therapeutic areas
- OncologyImmunology
- Modalities
- DNA decoy therapeuticssingle chain antibody platformoligonucleotides
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Financials
- Market cap
- $278.3M
- Total revenue
- $2.9M
- Enterprise value
- $291.9M
Beyond the preview
Go deeper on Valerio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valerio Therapeutics.